Meanwhile, the S&P BSE Sensex was down 34.11 points, or 0.17%, to 19,996.66.

On BSE, 2.73 lakh shares were traded in the counter as against an average daily volume of 43,706 shares in the past one quarter.

The stock hit a high of Rs 724.80 and a low of Rs 660.05 so far during the day. The stock had hit a 52-week high of Rs 2,019.90 on 29 May 2012. The stock had hit a 52-week low of Rs 595 on 26 March 2013.

The stock had outperformed the market over the past one month till 27 May 2013, rising 17.76% compared with the Sensex's 3.86% rise. The scrip had, however, underperformed the market in past one quarter, sliding 18.71% as against Sensex's 4.59% rise.

The small-cap company has an equity capital of Rs 5 crore. Face value per share is Rs 2.

The promoter of the company, AstraZeneca Pharmaceuticals AB Sweden, has offered to sell 37.49 lakh shares, or 15% of the total equity of the company, through offer-for-sale (OFS) route on stock exchanges today, 28 May 2013.

Promoter fixed a floor price of Rs 490 per share, which is 38.65% discount to the stock's closing price of Rs 798.65 on Monday, 27 May 2013. The floor price is 29.29% discount to the ruling market price.

AstraZeneca Pharma got bids for 44,790 shares compared to 37.49 lakh shares on offer as of 11:05 IST. The OFS is subscribed 1.19% at an indicative bid price of Rs 525.73 per share.

As on 31 March 2013, AstraZeneca Pharmaceuticals AB Sweden held 90% stake in Astrazeneca Pharma India. The OFS is launched to meet market regulator Sebi's norm on minimum public shareholding.

According to the Sebi norm, all private sector companies need to have minimum 25% public shareholding by 30 June 2013.

Astrazeneca Pharma India reported net loss of Rs 18.58 crore in Q4 March 2013 as against net loss of Rs 33.01 crore in Q4 March 2012. Net sales rose 3.4% to Rs 94.85 crore in Q4 March 2013 over Q4 March 2012.

AstraZeneca Pharma India is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease in important areas of healthcare. AstraZeneca Pharma India is involved in both the manufacturing and marketing of medicines.